Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency.
Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency.
复制标题
DOI:
10.15252/emmm.201404092
复制
发表时间:
2014-08
影响因子:
11.1
通讯作者:
Hirano M
中科院分区:
文献类型:
--
作者:
Garone C;Garcia-Diaz B;Emmanuele V;Lopez LC;Tadesse S;Akman HO;Tanji K;Quinzii CM;Hirano M
Autosomal recessive mutations in the thymidine kinase 2 gene (TK2) cause mitochondrial DNA depletion, multiple deletions, or both due to loss of TK2 enzyme activity and ensuing unbalanced deoxynucleotide triphosphate (dNTP) pools. To bypass Tk2 deficiency, we administered deoxycytidine and deoxythymidine monophosphates (dCMP+dTMP) to the Tk2 H126N (Tk2−/−) knock-in mouse model from postnatal day 4, when mutant mice are phenotypically normal, but biochemically affected. Assessment of 13-day-old Tk2−/− mice treated with dCMP+dTMP 200 mg/kg/day each (Tk2−/−200dCMP/dTMP) demonstrated that in mutant animals, the compounds raise dTTP concentrations, increase levels of mtDNA, ameliorate defects of mitochondrial respiratory chain enzymes, and significantly prolong their lifespan (34 days with treatment versus 13 days untreated). A second trial of dCMP+dTMP each at 400 mg/kg/day showed even greater phenotypic and biochemical improvements. In conclusion, dCMP/dTMP supplementation is the first effective pharmacologic treatment for Tk2 deficiency. Subject Categories Genetics, Gene Therapy & Genetic Disease; Metabolism
登录
查看更多内容
影响因子:
3.5
作者:
Lopez, Luis C.;Akman, Hasan O.;Hirano, Michio
通讯作者:
Hirano, Michio
影响因子:
30.8
作者:
Bourdon, Alice;Minai, Limor;Rotig, Agnes
通讯作者:
Rotig, Agnes
DOI:
10.1007/978-1-61779-504-6_9
发表时间:
2012-01-01
期刊:
MITOCHONDRIAL DISORDERS: BIOCHEMICAL AND MOLECULAR ANALYSIS
影响因子:
--
作者:
Marti, Ramon;Dorado, Beatriz;Hirano, Michio
通讯作者:
Hirano, Michio
影响因子:
30.8
作者:
Saada, A;Shaag, A;Elpeleg, O
通讯作者:
Elpeleg, O
影响因子:
3.5
作者:
Bulst, Stefanie;Abicht, Angela;Horvath, Rita
通讯作者:
Horvath, Rita